LVV Lot Release Testing

Lentiviral vectors (LVVs) are essential to modern cell and gene therapies, enabling stable gene transfer for transformative treatments. However, bringing these therapies to market requires navigating distinct scientific and operational challenges. Unlike other viral platforms, LVVs rely on retroviral biology, functional infectivity, and multi-plasmid production systems that introduce potential risks such as replication-competent lentivirus (RCL) and residual DNA complexities. Managing these variables demands safety-focused, biologically driven release testing.

Minaris Advanced Testing provides tailored, streamlined testing panels that integrate critical safety, potency, identity, and purity assays—including amplification-based RCL detection and cell-based potency testing. Designed around established quality systems and rigorous regulatory standards, these services deliver reliable disposition decisions and support safe patient delivery.

Download the full flyer to explore complete testing panels and assay specifications.